Endologix

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Endologix sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).

17 total trials 3 currently recruiting 11 completed top decile by trial count

Endologix: 17 sponsored US clinical trials, 3 recruiting.

Endologix sponsors 17 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 11 completed. The most-studied condition in this pipeline is Abdominal Aortic Aneurysm, with 3 trials.

Top-decile sponsor footprint

Endologix ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

17 total, page 1 of 1

RECRUITING

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

NCT06315023

RECRUITING

The Long-Term EVAR Assessment and Follow-Up (LEAF) Study for the AFX2 System

NCT06990048

RECRUITING NA

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

NCT05064540

ACTIVE NOT RECRUITING NA

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

NCT04252573

ACTIVE NOT RECRUITING NA

TORUS 2 IDE Clinical Study

NCT04130737

ACTIVE NOT RECRUITING NA

EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study

NCT03298477

COMPLETED NA

Detour2 Continued Access Study

NCT04625660

COMPLETED NA

The DETOUR 2 Clinical Trial

NCT03119233

COMPLETED NA

Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft Investigational Device Exemption (IDE) Study

NCT02949297

COMPLETED NA

Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices

NCT02407457

COMPLETED NA

Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System

NCT01726257

COMPLETED NA

Safety and Effectiveness Trial of the Ventana Fenestrated Stent Graft System

NCT01491945

COMPLETED NA

Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System

NCT01348828

COMPLETED NA

Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial

NCT01070069

COMPLETED NA

34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms

NCT00706394

COMPLETED NA

Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm

NCT00739401

COMPLETED NA

Powerlink Bifurcated Stent Graft Long-Term Follow-up Study

NCT00543270

What is open in the Endologix pipeline

3 recruiting of 17 indexed (18% open); 11 completed (65%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Abdominal Aortic Aneurysm (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Endologix: open-pipeline peers nationwide

Peers matched on 17 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Endologix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1520253035 0%5%10%15%20%25% Total trials Recruiting share EndologixAchieve Life SciencesBioDelivery Sciences InternationalChugai PharmaceuticalConvaTecNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders NetworkSanford HealthWoman's
Endologix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Endologix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 17 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Endologix page

17 registered trials is a research-attention snapshot, not an endorsement of Endologix or any single study.

  • 3 of Endologix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Abdominal Aortic Aneurysm is the condition Endologix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Abdominal Aortic Aneurysm trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Endologix pipeline card: 17 registered trials from official public datasets.Report a data error.